Drug Trial Radar · NCT00514007
Study of Continuous OSI-906 Dosing
Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
95
Actual
Start
Jun 18, 2007
Primary completion
Mar 19, 2012
Study completion Mar 19, 2012
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Aug 9, 2007
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.
Conditions
- Advanced Solid Tumors
Interventions
OSI-906Drug
OSI-906 administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the maximum tolerated dose (MTD) for both the once daily (QD) and twice daily (BID) dosing schedules and establish a recommended phase 2 dose of oral OSI-906Time frame: 21 days
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Vanderbilt Universtiy Medical Center
Nashville, Tennessee
The Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.